Daiichi Sankyo And AstraZeneca's DATROWAY EU Application Validated For First Line Metastatic TNBC Without Immunotherapy Option Supported By TROPION-Breast02 OS And PFS Improvements

Benzinga · 2d ago
  • Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca's DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population
  • If approved, DATROWAY could become the standard of care in this setting